Injectable contraceptives

1. www.freelivedoctor.com

2. Introduction
Injectable contraceptives
contain hormonal drugs that
provide women with safe,
highly effective, and
reversible contraceptive
protection.
www.freelivedoctor.com

3. Two types of injectable Two types of injectable
contraceptives : contraceptives :
(1) Progestogen-only formulations
that contain a progestogen hormone
and are effective for 2 or 3 months;
and,
(2) Combined formulations that
contain both a progestogen and an
estrogen and are effective for 1
month
www.freelivedoctor.com

4. Progestogen -only formulations Progestogen -only formulations
•Consist of DMPA (depot med-
roxyprogesterone acetate) and NET-EN
(norethisterone enanthate).
•DMPA is the injectable formulation
most widely used worldwide.
•DMPA is injected every 3 months.
•NET-EN is injected every 2 months.
www.freelivedoctor.com

5. Combined formulations
–The most extensively studied
formulations are known by their
brand names, Mesigyna;
–Monthly injectable.
–Mesigyna contains the same
progestogen as NET-EN.&
contains an added estrogen.
www.freelivedoctor.com

6. Combined formulations
Administered by a deep
intramuscular injection into
the muscle of the arm or
buttock and are effective
immediately, provided they
are taken at specified times
www.freelivedoctor.com

7. All injectable contraceptives are
slowly absorbed into the
bloodstream from the injection
site, with the body maintaining
a sufficient level of hormone to
provide contraception for 1 to
3 months, depending on the
type of injectable used
www.freelivedoctor.com

8. Common
trade names
Duration of
effect
Active
ingredients
Name
Depo-Provera,
Depo-Clinovir,
others
90 days
150 mg
medroxyprogesterone
acetate in an aqueous
microcrystalline
suspension
DMPA
(progestogen-
only)
Noristerat,
Norigest,
Doryxas, and
others
60 days
200 mg
norethisterone
enanthate
in an oily preparation
NET-EN
progestogen)
-only(
Mesigyna,
Norigynon
30 days
mg 50
norethisterone
enanthate and
mg estradiol 5
valerate
Mesigyna
(combined)
www.freelivedoctor.com

9. PROGESTOGEN
ONLY INJECTABLES
www.freelivedoctor.com

10. Mode of Action
•The immediate action of progestagen-only
injectables (POIs) is to thicken cervical
mucus, which then presents an obstacle to
sperm penetration.
•Also, ovulation is impaired.
•There are additional changes in the
endometrium that make it unfavourable to
implantation; however, the first two effects
make fertilisation highly unlikely.
www.freelivedoctor.com

11. Efficacy
The reported failure rates of
POIs are low, and come
within the narrow range of
0.1% to 0.6%.
www.freelivedoctor.com

12. Beneficial Effects
•Prevention of pregnancy
•A single injection of a POI can provide highly
effective protection against pregnancy for two or
more months, depending on the formulation.
•Delivery is simple, independent of coitus, and
ensures periodic contact with medical or other
trained health personnel.
•This is a suitable method for women in whom
oestrogens present health risks – eg, those
with a history of thromboembolic disorders - and
those who have had side effects with the use of
oestrogens.
www.freelivedoctor.com

13. Non-contraceptive health benefits
Clear benefits
•Sickle cell disease: In a two-year
trial, women with sickle cell disease
using DMPA had significantly fewer
crises than women given a placebo.
•Anaemia: POIs can increase
haemoglobin concentration, mainly
by reducing menstrual blood loss.
www.freelivedoctor.com

14. Non-contraceptive health benefits
Possible benefits
1. Endometrial cancer:
•In a World Health Organization (WHO) study, women who had
ever used DMPA had one-fifth the risk of developing
endometrial malignancy observed in women who had not used
DMPA.
•The results, although not statistically significant, support the
hypothesis that use of DMPA might protect against this form of
cancer.
2. Other:
•The use of POIs possibly protects against pelvic inflammatory
disease (PID), seizures in women with epilepsy, uterine myoma,
and endometriosis.
www.freelivedoctor.com

15. PROGESTOGEN ONLY PROGESTOGEN ONLY
INJECTABLESINJECTABLES
SIDE EFFECTS
www.freelivedoctor.com

16. Menstrual irregularities
•DMPA and NET-EN are associated
with disruptions of the menstrual
cycle including amenorrhoea,
prolonged menses, spotting between
periods, and heavy bleeding.
•Less than one-third of women
receiving DMPA report having normal
menstrual cycles during the first year
of use.
www.freelivedoctor.com

17. Menstrual irregularitiesMenstrual irregularities
•Amenorrhoea is the most common
side-effect and its occurrence
increases with duration of use from
about 50 % of DMPA users by the
end of one year to 80% by the end
of 5 years.
•Women using NET-EN are less likely
to experience amenorrhoea.
www.freelivedoctor.com

18. Menstrual Menstrual irregularitiesirregularities
•Heavy bleeding is uncommon (occurs in
1-2% of users), and prolonged bleeding is
seldom heavy enough to be a threat to
health.
•Any woman who reports prolonged or
heavy bleeding may need to be
evaluated for anemia.
• Anaemia treatments include nutritional
advice & an appropriate dosage of oral
iron tablets.
www.freelivedoctor.com

19. Menstrual irregularitiesMenstrual irregularities
•Treatments for heavy bleeding include
non-aspirin anti-inflammatory drugs such
as ibuprofen, short-term use of combined
oral contraceptives or estrogen, or early
administration of the next injection (not
sooner than 4 weeks after the previous
injection).
•If these measures are not effective or the
woman’s health is threatened, POIs
should be discontinued.
www.freelivedoctor.com

20. Other Side-EffectsOther Side-Effects
•After menstrual changes, weight gain,
headache, and dizziness are the next most
common side-effects reported.
•Most users of POIs put on weight and this is a
common reason for discontinuation.
•The average DMPA user gains 1.5–2.0 kg in
the first year and some users continue to gain
weight thereafter at about the same rate.
•In clinical trials, between 3% and 19% of users
of injectables have reported headache or
dizziness. Few women discontinue for these
reasons.
www.freelivedoctor.com

21. Possible CarcinogenicityPossible Carcinogenicity
•Clinical studies have found no association
between DMPA use and cervical, ovarian, or
liver cancers,
• And have confirmed a substantial protective
effect against endometrial cancer.
•Studies have found no overall increase in
risk of breast cancer.
•Although some studies have indicated a small
increased risk of breast cancer in some younger
women following initial exposure, the studies
show no trend toward increased risk among
more long-term users.
www.freelivedoctor.com

22. Bone densityBone density
•Findings to date suggest a relatively small
and reversible effect, with no serious
health risk for women of any age.
•At present, medical experts recommend no
restriction on use of injectables by
adolescents over age 16.
•Changes in calcium uptake by bone and
decreases in urinary calcium excretion have
been documented and there is a
suggestion of a relation between long
term use of DMPA and low bone mass.
www.freelivedoctor.com

23. EffectEffect on fetal exposureon fetal exposure
•There are no known adverse effects of fetal
exposure to injectables.
•Studies of teenage children who were exposed
to DMPA in utero show no significant
differences in health, growth, or sexual
development compared to other children.
•Progestogen-only injectables can be used by
breastfeeding women at 6 weeks postpartum
without adverse effects on nursing infants.
www.freelivedoctor.com

24. Effect on MetabolismEffect on Metabolism
•The only metabolic effect of undoubted clinical
importance is weight gain.
•- Minor alterations of lipid metabolism,
fluid/nitrogen balance, glucose tolerance,
steroid metabolism, and immune function
have been recorded but seem to be of no
clinical significance.
•- Fewer data have been published on the
metabolic effects of NET-EN, but its effect on
most biochemical functions appears to be similar
to that of DMPA.
www.freelivedoctor.com

25. Cardiovascular EffectCardiovascular Effect
•Data are insufficient to indicate whether there
is any relation between DMPA use and
cardiovascular complications.
•Results of a WHO study suggest that there is
little or no increased risk of cardiovascular
disease associated with the use of
progestagen-only injectables, although further
investigation is needed into a possible
increased risk of stroke among women with
high blood pressure.
www.freelivedoctor.com

26. RETURN OF FERTILITYRETURN OF FERTILITY
•Fertility is not impaired after discontinuation of
DMPA or NET-EN although its return is delayed.
•The average time between the last DMPA injection
and conception is about nine months, including the
three months during which the injection is effective.
• More than 80% of women become pregnant within
one year of discontinuing DMPA and 90% within
two years.
• The few data on NET-EN suggest that fertility
returns more quickly with this agent.
www.freelivedoctor.com

27. www.freelivedoctor.com

28. World Health Organization (WHO) developed eligibility
criteria for the use of various contraceptive methods .
•Category 1: A condition for which there is no restriction for
the use of the contraceptive method.
•Category 2: A condition where the advantages of using the
method generally outweigh the theoretical or proven risks.
•Category 3: A condition where the theoretical or proven
risks usually outweigh the advantages of using the method.
•Category 4: A condition which represents an unacceptable
health risk if the contraceptive method is used.
www.freelivedoctor.com

29. Contra-indicationsContra-indications
:((category 4:((category 4
POIs should not be used in
the presence of:
2.Confirmed or suspected
pregnancy
3.Malignant disease of the
breast
www.freelivedoctor.com

30. Conditions requiring careful Conditions requiring careful
:(consideration (category 3:(consideration (category 3
POIs should generally not be used in the
presence of:
2.Diabetes with vascular disease or of >20 years’
duration
3.Cerebrovascular or coronary artery disease
4.Acute liver disease
5. 4.benign or malignant liver tumours
6.Severe hypertension/ (BP>180/110 mm Hg)
7.Hypertension with vascular disease
8.Focal migraine.
9.severe cirrhosis
www.freelivedoctor.com

31. OtherOther Conditions (category 2)Conditions (category 2)
- Women with mild to moderate hypertension,
diabetes (without vascular complications),
hyperlipidaemias, or mild (compensated)
cirrhosis can generally use POIs.
- Careful screening and appropriate
monitoring will allow the benefits of using
POIs to outweigh any potential risks.
www.freelivedoctor.com

32. COMBINED COMBINED
INJECTABLE INJECTABLE
CONTRACEPTIVESCONTRACEPTIVES
www.freelivedoctor.com

33. Mode of ActionMode of Action
•Combined injectable contraceptives (CICs)
exert their contraceptive effect mainly by
suppressing ovulation.
•In addition, thickening of the cervical
mucus (mainly due to the progestagen)
presents an obstacle to sperm penetration.
•The receptivity of endometrium to the
blastocyst is also reduced.
www.freelivedoctor.com

34. EfficacyEfficacy
•In clinical trials, Cyclofem
/Cycloprovera and
Mesigyna/Norigynon have both
proved highly effective
contraceptives
•With 12-month failure rates of 0.2%
or less for Cyclofem and 0.4% for
Mesigyna.
www.freelivedoctor.com

35. Beneficial EffectsBeneficial Effects
•A single injection of a CIC can
provide highly effective protection
against pregnancy for one month.
• Delivery is simple and independent
of coitus, and in general CICs are
associated with better cycle control
than POIs.
www.freelivedoctor.com

36. Side-EffectsSide-Effects
•In clinical trials, side-effects of CICs
included irregular bleeding,
amenorrhoea, heavy bleeding,
prolonged bleeding, headaches,
dizziness, and body weight changes.
•However, these side-effects are much less
common than with the use of POIs.
www.freelivedoctor.com

37. ReturnReturn of Fertilityof Fertility
•The return of fertility following CIC
use is noticeably shorter than that
observed for POIs.
•More than 50% of women become
pregnant within six months of
discontinuing CICs and 80% within
one year.
www.freelivedoctor.com

38. Eligibility CriteriaEligibility Criteria
Until sufficient clinical data become
available, the eligibility criteria for
the use of combined injectable
contraceptives are based on data
from combined oral
contraceptives
www.freelivedoctor.com

39. www.freelivedoctor.com

40. AdolescentsAdolescents
Injectable contraceptives have
important advantages in
adolescents; however, in those under
16 years of age there are concerns
regarding the hypo-oestrogenic
effects of POIs, which may affect the
post-menarche increase of bone
mineral density.
www.freelivedoctor.com

41. Women Over 35Women Over 35
•POIs and CICs can be used by most
healthy women over 35.
•Any increase in risk of
cardiovascular disease will be
minimal for these women if they do
not smoke and have no other risk
factors, such as hypertension or
diabetes.
www.freelivedoctor.com

42. Postpartum Postpartum
((in Breast feeding Women((in Breast feeding Women
•If a woman wishes to start injectable
contraception during breastfeeding a POI
should be recommended.
•DMPA and NET-EN have no apparent
negative influence on milk production or the
duration of lactation; and infants whose
mothers have received DMPA while
breastfeeding seem to develop normally, both
physically and mentally.
www.freelivedoctor.com

43. Postpartum Postpartum
(in Breast feeding Women)(in Breast feeding Women)
•The question of possible
consequences of the transfer of the
injectable steroid to the breastfed
infant has yet to be resolved.
•The amounts of steroid transmitted in the
milk and absorbed by the infant are
known to be small.
www.freelivedoctor.com

44. Postpartum Postpartum
(in Breast feeding Women)(in Breast feeding Women)
•Short-term follow-up studies of children
breastfed by mothers using progestagen-
only contraceptives have given reassuring
results, but longer-term studies are yet to
be evaluated.
•It is recommended that breastfeeding
women should not start POIs before
the sixth week postpartum.
www.freelivedoctor.com

45. Postpartum Postpartum
((in Breastfeeding Women((in Breastfeeding Women
•There are no data on the effects of CIC
formulations on the quantity and
quality of breast milk or the duration of
lactation.
•Until such data become available, CICs
should generally be withheld until six
months after delivery or until the infant
is weaned, whichever is the earlier
www.freelivedoctor.com

46. Postpartum Postpartum
((in Non-Breast feeding Women((in Non-Breast feeding Women
•To avoid increasing the risk of
thromboembolic complications in the
postpartum period, CICs should not be
used during the first three weeks after
delivery.
• After 21 days, blood coagulation and
fibrinolysis are essentially back to normal.
• POIs can be started at any time after
delivery.
www.freelivedoctor.com

47. Drug InteractionDrug Interaction
•Drugs that induce liver enzymes may
lessen the efficacy of hormonal
contraceptives.
•Such drugs which are commonly used in
long-term treatments include the
antibiotics rifampicin and griseofulvin
and the anticonvulsants phenytoin,
carbamazepine, and barbiturates.
www.freelivedoctor.com

48. Prevention of STD/HIV TransmissionPrevention of STD/HIV Transmission
•Strict aseptic techniques should be
maintained when giving the injections to avoid
the risk of transmitting any infection including
HIV.
•Injectable contraceptives do not protect
against STD/HIV infection.
•Therefore, when there is a risk of sexual
transmission of infection, condoms should
always be used in addition to injectable
contraceptives.
www.freelivedoctor.com

49. Elective SurgeryElective Surgery
•It is advisable to stop using CICs about four
weeks before elective surgery that will involve
prolonged immobilisation, and to restart them
two weeks after the woman has returned to
mobility.
•Alternative effective contraception, including
POIs, should be advised during this time.
• In emergency procedures, the surgeon may
consider prophylactic anticoagulant
measures
www.freelivedoctor.com

50. Sickle Cell DiseaseSickle Cell Disease
•Either POIs or CICs can be used
by women with sickle cell disease
but POIs are a more suitable
choice.
•In addition to their contraceptive
effect, there is some evidence of
benefit on the disease itself.
www.freelivedoctor.com

51. CounsellingCounselling
•Clients considering the use of injectable
contraception should be clearly informed about
the advantages and disadvantages of the
agents, their side-effects, their cost, and the
alternative contraceptive options.
•Where once-a-month injectables are available,
clients should be told about the differences
between these injectables and POIs.
•Women who desire a rapid return to fertility
on discontinuation of their contraceptive should
be advised to use CICs where available or
another method.
www.freelivedoctor.com

52. some misconceptions some misconceptions
about injectablesabout injectables
www.freelivedoctor.com

53. Do injectable contraceptives Do injectable contraceptives
cause infertility ?cause infertility ?
No.
Although a woman's return to fertility
can be delayed after injectables are
discontinued, injectables do not
damage fertility.
www.freelivedoctor.com

54. Do injectable contraceptives Do injectable contraceptives
increase cancer risks increase cancer risks ??
No.
Overall increase in cancer risk has
not been demonstrated in long-
term, multicountry studies of
injectable users.
www.freelivedoctor.com

55. When amenorrhea occurs, does When amenorrhea occurs, does
menstrual blood build up in the menstrual blood build up in the
body, leading to disease body, leading to disease??
No.
Amenorrhea is not a health
risk.
It does not cause blood to build
up in the body.
www.freelivedoctor.com

56. Can injectable contraceptives Can injectable contraceptives
transmit disease transmit disease ??
•No.
•Injectable contraceptives are sterile
preparations that are free from
disease- causing agents.
•Contaminated needles and syringes
used to administer injectables can
transmit disease, however.
www.freelivedoctor.com

57. special injection special injection
techniques techniques
www.freelivedoctor.com

58. •Injectable contraceptives are
administered using deep
intramuscular injection
techniques.
•The injection site should not
be massaged afterwards,
since this may accelerate
absorption of the drug.
www.freelivedoctor.com

59. •Because DMPA is an aqueous
suspension, a DMPA vial must be
shaken vigorously before it is
loaded into the syringe, to
resuspend any active ingredient in
the bottom of the vial.
•The syringe should then be checked
to ensure that it contains the correct
dosage.
www.freelivedoctor.com

60. •NET-EN is an oil-based solution
that needs special care to ensure
that all the solution is both loaded
and injected without leakage.
•Warming the vial to body
temperature makes it easier to
draw into the syringe.
•Since Mesigyna is an oil-based
solution similar to NET-EN, the
same attention to leakage applies.
www.freelivedoctor.com

61. When can the initial When can the initial
injection be giveninjection be given? ?
www.freelivedoctor.com

62. Progestogen -Only InjectablesProgestogen -Only Injectables
•DMPA and NET-EN :
•During the first 7 days of the menstrual
cycle.
•Injectables will be immediately effective.
•Immediately after abortion.
•At other times in a menstrual cycle as long
as the possibility of pregnancy is ruled out.
•At 6 weeks postpartum.
www.freelivedoctor.com

63. Combined InjectablesCombined Injectables
Mesigyna Mesigyna
•During the first 5 days of the menstrual
cycle.
•Injectables will be immediately
effective.
•Immediately after abortion.
•At other times in a menstrual cycle as
long as the possibility of pregnancy is
ruled out.
•At 6 months postpartum.
www.freelivedoctor.com

64. Margin for Margin for
the follow-up the follow-up
re-injection re-injection
www.freelivedoctor.com

65. •Progestogen-Only InjectablesProgestogen-Only Injectables
DMPA and NET-EN:DMPA and NET-EN:
up to 2 weeks (14 days) early or up to 2 weeks (14 days) early or
latelate
•Combined Injectables
Mesigyna:
Up to 3 days early or late
www.freelivedoctor.com

66. Breast feedingBreast feeding
•Progestogen-Only Injectables
DMPA and NET-EN:
Suitable for women who are breastfeeding at
6 weeks postpartum.

•Combined Injectables
Mesigyna:
Not suitable for women who are fully breast
feeding until 6 months postpartum.
www.freelivedoctor.com

67. www.freelivedoctor.com